In a single week in March 2025, three senior PBM executives announced departures. OptumRx's Chief Commercial Officer, Caremark's SVP of Formulary Strategy, and Express Scripts' VP of Employer Accounts all left for roles outside the traditional PBM sector. Two went to startup transparent PBMs; one joined a health system building its own pharmacy benefit operation.
The exits are part of a broader pattern. Since January 2024, at least 18 VP-level or above executives have left the Big 3 PBMs. The destinations cluster in three categories: transparent/pass-through PBMs (Mark Cuban Cost Plus, Capital Rx, Rightway), health system-owned PBMs, and health tech companies building direct manufacturer-to-patient models.
Industry recruiters describe the talent flow as driven by both push and pull factors. On the push side, FTC scrutiny, congressional investigations, and state-level regulation have created career risk for executives associated with traditional rebate-based PBM models. On the pull side, venture-funded challengers are offering equity packages that dwarf Big 3 retention offers.
For plan sponsors, the executive migration is a leading indicator. When senior formulary and commercial talent moves to transparent models, it accelerates the competitive pressure on legacy PBMs. The departing executives carry deep knowledge of rebate structures, manufacturer negotiation tactics, and formulary management techniques.
